Ageing Research Reviews Review Time
Ageing Research Reviews review time depends on whether the manuscript reads as a true critical review with a clear synthesis thesis, search boundary, and mechanism map.
While you wait
Waiting on a decision? Get your next move ready.
The wait is out of your hands; the next move isn't. Scan your next manuscript free, or run this paper through the scan to see what reviewers typically push back on, so the revision response is ready when the decision lands.
Quick answer: for Ageing Research Reviews review time, a fast editorial screen can return in about 6 days, while a manuscript sent for external review should be planned around 6 to 10 weeks before first decision, per ScienceDirect journal insights, Elsevier guide-for-authors workflow, and current SciRev author-reported timing.
That range is not a promise from Elsevier. The public journal insight mixes fast screening with reviewed manuscripts. The useful planning question is whether your review article has a clear synthesis thesis, explicit literature boundary, disease-relevant mechanism map, and figures that help reviewers judge the field instead of only reading a broad summary.
If you are still deciding whether the manuscript belongs at ARR, use the Ageing Research Reviews submission guide. If the manuscript is already in the portal and you need to interpret a status label, use the Ageing Research Reviews under-review guide.
Last reviewed July 20, 2026.
Ageing Research Reviews review time at a glance
Stage | Practical planning range | What is happening |
|---|---|---|
Administrative intake | 1 to 5 days | Source basis: Elsevier submission checks, file completeness, metadata, authorship, declarations, and basic scope routing. |
Editorial screen | About 6 days for submission to first decision in current ScienceDirect insights | Source basis: ScienceDirect journal page; fast decisions often include editorial-screen outcomes before external review. |
Reviewer recruitment | 1 to 3+ weeks | Source basis: ARR needs reviewers who can evaluate ageing mechanism, disease relevance, review method, and synthesis argument. |
Decision after review | 54 days in current ScienceDirect insights | Source basis: ScienceDirect reports submission to decision after review; this is the best public first-party planning number for reviewed manuscripts. |
Full acceptance path | 98 days in current ScienceDirect insights | Source basis: ScienceDirect reports submission to acceptance for accepted manuscripts. |
Stress case | 10+ weeks without movement | Source basis: status-owner patterns and reviewer-recruitment reality; a polite inquiry becomes reasonable around this point. |
The important distinction is screen time versus review time. A quick first decision may be a return, rejection, or other editorial action. A paper that enters outside review has a different timing profile because reviewers need to assess whether the review is genuinely critical and current.
What the live sources say
The current ScienceDirect Ageing Research Reviews journal page lists journal-level insights: 6 days from submission to first decision, 54 days from submission to decision after review, 98 days from submission to acceptance, and 2 days from acceptance to online publication. It also lists the journal as supporting open access, with a current open-access APC shown as USD 5,460 excluding taxes.
The current Elsevier guide for authors explains that Ageing Research Reviews follows single-anonymized peer review. The editor first checks suitability; if suitable, the manuscript is typically sent to at least two reviewers for independent assessment of scientific quality. The same guide lists the relevant article formats: Review Article, Short Review, and View Point.
The current SciRev community page for Ageing Research Reviews shows 1 review, 0.7 months for duration of first review round, 0.7 months total handling time for accepted manuscripts, 2.0 reports, and a latest review noting a 3.0 week first review round. That sample is too small to treat as a stable median, but it supports the same practical point: reviewed ARR manuscripts can move quickly when reviewer fit and synthesis clarity are strong.
Why ARR review time can be short on paper but longer in practice
Ageing Research Reviews is a review journal, not a primary research journal. That changes the review burden.
Reviewers are usually asking:
- Is this a critical review, short review, or viewpoint that fits the journal's article types?
- Does the manuscript explain why this review is needed now?
- Is the literature-search boundary clear enough to audit?
- Are mechanisms of ageing tied to age-related disease, lifespan, healthspan, or intervention relevance?
- Do figures synthesize mechanisms, controversies, or decision points rather than decorating the text?
- Are recent findings integrated with established mechanisms instead of appended as a final section?
- Would a narrower disease journal, molecular-medicine review journal, or gerontology venue own the audience better?
Those checks can move quickly when the review has a strong thesis. They can slow when reviewers have to rebuild the selection logic, mechanism map, or disease relevance themselves.
How to interpret silence after submission
Elapsed time | What it usually means | What to do |
|---|---|---|
First week | Intake, suitability screen, or fast editorial decision | Do not assume full peer review has started just because the portal is quiet. |
Week 2 to 3 | Editor routing or reviewer invitations | Prepare the synthesis thesis and literature-boundary defense. |
Weeks 4 to 8 | Normal reviewed-manuscript window | Expect reviewer comments on scope, mechanism, search logic, figures, and "why now." |
Weeks 8 to 10 | Possible late report or editor synthesis | Keep preparing a revision map; a follow-up is usually premature unless the portal requests action. |
After 10 weeks | Reviewer delay, recruitment issue, or synthesis bottleneck | A concise inquiry with the manuscript ID becomes reasonable. |
Silence is not a decision signal. At ARR, it more often means reviewer recruitment, active review, or editor synthesis across ageing-mechanism and disease-relevance perspectives.
What usually slows ARR first decision
- Review article summarizes instead of synthesizes. A broad literature tour can be readable but still weak if it does not take a position.
- Search boundary is implicit. Reviewers cannot tell which papers were included, excluded, or treated as foundational.
- Mechanism-to-disease link is thin. Cellular or molecular mechanisms need to connect to age-related disease, lifespan, healthspan, or intervention relevance.
- Figures are decorative. ARR reviewers expect figures that clarify mechanisms, controversies, or future directions.
- Recent literature is uneven. Ageing biology moves quickly; gaps in senescence, epigenetic clocks, inflammaging, proteostasis, mitochondrial biology, neurodegeneration, or intervention literature can trigger revision.
- Article type is unclear. A Short Review, View Point, and in-depth Review Article create different reviewer expectations.
These are timing risks because they create extra editorial work. A manuscript with unclear synthesis may still be worth reviewing, but reviewers will spend the first round asking the authors to sharpen the frame.
ARR-specific failure patterns that make review slow
Ageing Research Reviews thesis appears only after the literature tour. In ARR-targeted manuscripts we review, the most common slow-review pattern is a paper that spends pages proving the authors have read the field before it states what the review changes. The reviewer then has to infer the synthesis thesis from section order, figure choices, and selected references. The fix is testable: the abstract, introduction, first figure, and section headings should all name the same review contribution.
Ageing Research Reviews search boundary is not auditable. A review can cite hundreds of papers and still leave reviewers unsure about selection logic. This is especially risky when the topic spans senescence, inflammation, metabolism, neurodegeneration, cardiovascular ageing, and intervention biology. If the manuscript does not state database scope, date range, inclusion criteria, exclusion logic, or narrative-selection rationale, reviewers may ask for a stronger methods paragraph or a rewritten scope statement.
Ageing Research Reviews mechanism map does not connect scales. ARR's scope favors cellular and molecular mechanisms of ageing and age-related disease, but many drafts stay at one scale. A molecular review may not explain organism-level relevance. A disease-oriented review may not show the mechanistic chain. A translational review may not separate human evidence from model-organism inference. Reviewers slow down when the manuscript makes them build the cross-scale map.
Ageing Research Reviews figures restate pathways instead of resolving reviewer decisions. A figure that lists molecules is less useful than a figure that explains a controversy, causal sequence, intervention point, or competing model. In our pre-submission work, figure weakness is a timing risk because reviewers use figures to decide whether the review contributes synthesis. If the figures are decorative, the review feels less necessary even when the text is accurate.
Ageing Research Reviews "why now" argument is too generic. The journal is selective enough that "the field is growing" is not a strong reason. The manuscript should explain what changed: new intervention evidence, a methodological shift, contradictory results, ageing-clock debate, clinical translation failure, biomarker revision, or a new cross-disease mechanism. Without that urgency, the editor or reviewers may ask whether the review is timely enough.
Article-type differences inside ARR
ARR article shape | Review-time implication |
|---|---|
Review Article | Can take the longest because reviewers test coverage, mechanism synthesis, figure logic, and whether the review advances the field. |
Short Review | Can move faster if the question is narrow and timely, but slows if the focus is not sharp enough for a short format. |
View Point | Can receive faster editorial pushback if it reads as opinion without enough evidence; full review depends on whether the argument is anchored in current literature. |
Systematic or structured review | Reviewers focus hard on search method, inclusion/exclusion rules, bias handling, and whether conclusions exceed evidence. |
The review-time lesson is that article type should be explicit. A manuscript that behaves like a broad Review Article but is framed as a Short Review creates unnecessary reviewer friction.
What a faster ARR review usually has in common
The manuscripts that move more cleanly usually make the reviewer task obvious:
- the abstract states the synthesis thesis and why the review is needed now;
- the first figure maps the mechanism, controversy, or intervention logic;
- the search boundary or narrative-selection logic is explicit;
- recent literature is integrated throughout the argument, not bolted on;
- disease relevance is tied to mechanism rather than mentioned as background;
- figure legends explain the model, evidence level, and uncertainty;
- the cover letter names the article type and why ARR owns the audience.
That package can still take weeks. But it lowers the chance that reviewer reports become a request to rebuild the review architecture.
Readiness check
While you wait, scan your next manuscript.
The scan takes about 1-2 minutes. Use the result to decide whether to revise before the decision comes back.
Submit if
- The manuscript is clearly a Review Article, Short Review, or View Point that matches Elsevier's current article-type definitions.
- The abstract names a specific synthesis thesis, not just a topic area.
- The literature boundary is explicit enough for a reviewer to audit.
- The main figures synthesize mechanisms, controversies, or intervention logic.
- The review connects ageing mechanisms to age-related disease, lifespan, healthspan, or prevention relevance.
- The cover letter explains why ARR is the right audience and why the review is timely now.
Think twice if
- The review mostly summarizes literature without a position.
- The strongest argument appears only after several background sections.
- Recent evidence from the last few years is uneven or siloed by subsection.
- The figures are mostly pathway decoration rather than synthesis.
- The manuscript belongs more naturally at a disease-specific review journal, Mechanisms of Ageing and Development, Experimental Gerontology, GeroScience, or a clinical gerontology venue.
- You need a guaranteed fast decision; the public 6-day insight is not the same as guaranteed external-review timing.
What to do while waiting
- Draft a one-page synthesis map: thesis, search boundary, mechanism map, disease relevance, and "why now."
- Mark where each likely reviewer objection is answered in the manuscript.
- Update a table of the most recent key papers, especially papers published after the manuscript draft stabilized.
- Audit figure legends for mechanism, evidence level, model organism or human relevance, and uncertainty.
- Prepare a revision plan that distinguishes coverage expansion from thesis sharpening.
- Decide the best fallback venue if the decision says the review is sound but not ARR-shaped.
This is better than waiting passively. If the first decision is major revision, the response work is already organized.
Evidence basis and limits
This page uses current ScienceDirect journal insights, the current Elsevier guide for authors, the live Elsevier submission route, SciRev's current visible ARR page, and Manusights pre-submission review work with ageing-biology review manuscripts.
The key limitation is that the public numbers describe different populations. ScienceDirect's 6 days to first decision includes fast editorial-screen decisions; 54 days to decision after review is more relevant once outside review occurs; SciRev's 1 review is too small to establish a robust median. Treat all timing numbers as planning ranges, not guarantees.
Manusights read on ARR timing risk
In our pre-submission review work with Ageing Research Reviews and nearby ageing-biology review manuscripts, timing risk usually comes from review architecture, not sentence-level polish.
Ageing Research Reviews abstract promises coverage but not synthesis. Reviewers can tolerate a narrow review if the thesis is sharp. They are less forgiving when the abstract promises comprehensive coverage but never says what conceptual decision the review helps readers make. The manuscript component to fix is the abstract, not only the literature section.
Ageing Research Reviews figure package does not prove the review contribution. A strong ARR figure should help a reviewer see the mechanism map, disease relevance, controversy, or intervention logic quickly. If the figures could be copied into any ageing review with minor label changes, they are not doing enough work.
Ageing Research Reviews literature method is hidden in prose. Even narrative reviews need honest selection logic. The source-to-claim chain should be visible enough that reviewers know whether the manuscript is comprehensive, selective by design, or viewpoint-driven.
Ageing Research Reviews disease relevance is asserted rather than mapped. A review that names Alzheimer's disease, cardiovascular ageing, cancer, metabolic disease, or frailty still needs to show how the mechanism connects to that outcome. Reviewers slow down when they have to infer the translational bridge.
Before upload, an Ageing Research Reviews submission-readiness check can test whether the synthesis thesis, literature boundary, mechanism map, figures, and "why now" argument are strong enough before you commit to a multi-week review path.
Frequently asked questions
ScienceDirect currently reports 6 days from submission to first decision, 54 days to decision after review, and 98 days from submission to acceptance. For a manuscript sent to reviewers, plan around 6 to 10 weeks before a first decision, with longer waits when reviewer recruitment or synthesis disputes slow the process.
The 6-day first-decision insight includes fast editorial screening. A paper that enters external review has to be assessed for synthesis thesis, literature-search boundary, mechanistic accuracy, disease relevance, and figure logic, so the author-facing wait can be much longer.
Only weakly. A longer wait usually means the manuscript is past the fastest screen and is in reviewer recruitment, active review, or editor synthesis, but it does not predict acceptance.
If a manuscript has been under active review for about 10 weeks without status movement, a short portal or editorial-office inquiry with the manuscript ID is reasonable. Before then, silence often reflects reviewer recruitment or report timing.
Sources
Final step
Done interpreting the status? Put the wait to work.
The decision will arrive on the journal's clock. What you control is what's next: scan your next manuscript free, or run this paper through the scan so the likely reviewer pushback is mapped before the revision request lands.
Free scan, no card needed.
Anthropic Privacy Partner. Your manuscript is never used to train any model.